All In Biotech

BLA 761136 · Celgene Corp

Reblozyl

Luspatercept-Aamt · Subcutaneous · Erythroid Maturation Agent

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 8, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

57

12 Phase 3, 20 recruiting

FAERS reports

2,614

1,604 serious, 414 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 20, 2026.

REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ). 1.1 Beta Thalassemia REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. 1.2 Myelodysplastic Syndromes Associated Anemia REBLOZYL is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. 1.3 Myelodysplastic Syndromes with Ring Sideroblasts or Myelodysplastic/ Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis Associated Anemia REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts...

Mechanism: Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling. In models of β-thalassemia and MDS, luspatercept-aamt decreased abnormally elevated Smad2/3 signaling and improved hematology parameters associated with ineffective erythropoiesis in mice. Luspatercept-aamt promoted erythroid maturation through differentiation and increasing the percentage of late-stage erythroid precursors (normoblasts) in the bone marrow of mice and increased erythroid precursors in humans, thereby increasing erythropoiesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 28, 2023 Supplement 9 · Efficacy · priority review OrphanLabelLetter
  • Apr 3, 2020 Original approval · Efficacy NovelOrphanLabelLetterReview
  • Nov 8, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
  • REBLOZYL · LUSPATERCEPT-AAMT 75MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • REBLOZYL · LUSPATERCEPT-AAMT 25MG/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Luspatercept" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death244
  • off label use193
  • haemoglobin decreased144
  • fatigue137
  • drug ineffective114
  • weight decreased92
  • product storage error85
  • dizziness84
  • myelodysplastic syndrome75
  • dyspnoea73
  • fall70
  • asthenia57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20182
20193
2020142
2021248
2022440
2023325
2024494
2025536
2026424

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reblozyl (Luspatercept-Aamt)

2024 spending

$40.6M

Beneficiaries

402

3,028 claims

Per beneficiary

$101,095

$8,552.46 per unit

View as table
YearSpending
2020$10,550,369
2021$16,465,063
2022$19,913,471
2023$26,119,753
2024$40,640,022

Part B: Reblozyl (Luspatercept-Aamt) · HCPCS J0896

2024 spending

$755M

Beneficiaries

6,466

46,355 claims

Per beneficiary

$116,808

2024 ASP limit $40.31 per unit

View as table
YearSpending
2020$108,401,652
2021$266,191,359
2022$332,954,781
2023$451,098,388
2024$755,278,437

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.